188 related articles for article (PubMed ID: 25884512)
1. Genomics driven-oncology: challenges and perspectives.
Normanno N; Cree IA
BMC Cancer; 2015 Mar; 15():141. PubMed ID: 25884512
[TBL] [Abstract][Full Text] [Related]
2. Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.
Buettner R; Wolf J; Thomas RK
J Clin Oncol; 2013 May; 31(15):1858-65. PubMed ID: 23589544
[TBL] [Abstract][Full Text] [Related]
3. Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma.
Liu D; Vokes NI; Van Allen EM
Cancer Discov; 2017 Jun; 7(6):555-557. PubMed ID: 28576842
[TBL] [Abstract][Full Text] [Related]
4. Genomic alterations in lung adenocarcinoma.
Devarakonda S; Morgensztern D; Govindan R
Lancet Oncol; 2015 Jul; 16(7):e342-51. PubMed ID: 26149886
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers in lung adenocarcinoma: a decade of progress.
Sholl LM
Arch Pathol Lab Med; 2015 Apr; 139(4):469-80. PubMed ID: 25255293
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung.
Bernicker EH; Miller RA; Cagle PT
J Oncol Pract; 2017 Apr; 13(4):221-227. PubMed ID: 28399384
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
8. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
9. Genetic basis for susceptibility to lung cancer: Recent progress and future directions.
Yokota J; Shiraishi K; Kohno T
Adv Cancer Res; 2010; 109():51-72. PubMed ID: 21070914
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Advanced Non-Small Cell Lung Cancer in 2018.
Doroshow DB; Herbst RS
JAMA Oncol; 2018 Apr; 4(4):569-570. PubMed ID: 29494728
[No Abstract] [Full Text] [Related]
11. [KRAS and bronchial adenocarcinoma. Between disappointments and hopes].
Guibert N; Ilie M; Léna H; Didier A; Hofman P; Mazieres J
Rev Mal Respir; 2016 Feb; 33(2):156-64. PubMed ID: 26520779
[TBL] [Abstract][Full Text] [Related]
12. Successes and limitations of targeted cancer therapy in lung cancer.
Suda K; Mitsudomi T
Prog Tumor Res; 2014; 41():62-77. PubMed ID: 24727987
[TBL] [Abstract][Full Text] [Related]
13. Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
Jordan EJ; Kim HR; Arcila ME; Barron D; Chakravarty D; Gao J; Chang MT; Ni A; Kundra R; Jonsson P; Jayakumaran G; Gao SP; Johnsen HC; Hanrahan AJ; Zehir A; Rekhtman N; Ginsberg MS; Li BT; Yu HA; Paik PK; Drilon A; Hellmann MD; Reales DN; Benayed R; Rusch VW; Kris MG; Chaft JE; Baselga J; Taylor BS; Schultz N; Rudin CM; Hyman DM; Berger MF; Solit DB; Ladanyi M; Riely GJ
Cancer Discov; 2017 Jun; 7(6):596-609. PubMed ID: 28336552
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
Kristiansen C; Olsen KE; Hansen NC; Hansen KH; Hansen O
Acta Oncol; 2012 Sep; 51(7):948-9. PubMed ID: 22471746
[No Abstract] [Full Text] [Related]
15. [Diagnosis, prognosis, and prediction of non-small cell lung cancer. Importance of morphology, immunohistochemistry and molecular pathology].
Warth A
Pathologe; 2015 Nov; 36 Suppl 2():194-200. PubMed ID: 26391251
[TBL] [Abstract][Full Text] [Related]
16. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.
Saito M; Suzuki H; Kono K; Takenoshita S; Kohno T
Surg Today; 2018 Jan; 48(1):1-8. PubMed ID: 28280984
[TBL] [Abstract][Full Text] [Related]
17. Cell death in cancer therapy of lung adenocarcinoma.
Zagryazhskaya A; Gyuraszova K; Zhivotovsky B
Int J Dev Biol; 2015; 59(1-3):119-29. PubMed ID: 26374533
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.
Vigneswaran J; Tan YH; Murgu SD; Won BM; Patton KA; Villaflor VM; Hoffman PC; Hensing T; Hogarth DK; Malik R; MacMahon H; Mueller J; Simon CA; Vigneswaran WT; Wigfield CH; Ferguson MK; Husain AN; Vokes EE; Salgia R
Oncotarget; 2016 Apr; 7(14):18876-86. PubMed ID: 26934441
[TBL] [Abstract][Full Text] [Related]
19. [Development of molecular targeted therapies in lung cancers].
Suda K; Mitsudomi T
Nihon Geka Gakkai Zasshi; 2014 May; 115(3):130-6. PubMed ID: 24946519
[TBL] [Abstract][Full Text] [Related]
20. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
